AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of plerixafor given in addition to
granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells
(PBSCs) for autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and
multiple myeloma (MM). Efficacy outcomes include evaluation of fold increase in circulating
CD34+ cells from just before the first plerixafor injection to 10-11 hours post plerixafor
(just before apheresis) and assessment of successful polymorphonuclear leukocyte (PMN)
engraftment after transplantation. Data from this protocol will assist in the determination
of the dosing schedule for future studies.